

## Gastric mixed neuroendocrine/ nonneuroendocrine neoplasia: a rare entity

Keywords: Mixed neuroendocrine/non-neuroendocrine neoplasia. Mixed neuroendocrine/nonneuroendocrine neoplasms. Gastric cancer.

Dear Editor,

Gastric neoplasms have different histological subtypes. Mixed neuroendocrine/nonneuroendocrine neoplasms (MiNEN), as defined by the World Health Organization (WHO) 2019 Classification of Tumors of the Digestive System, are rare composite tumors bearing morphological characteristics of more than one histological type. Historically, the diagnosis requires that each component accounts for at least 30 % of the total tumor burden (1,2).

We present the case of a 70-year-old male, who was referred to our endoscopy unit for resection of a depressed lesion (Paris classification type 0IIc) of 40mm diameter, located on the lesser curvature of the gastric body. The lesion was submitted to *en bloc* resection by endoscopic submucosal dissection. Histological examination revealed a poorly differentiated intramucosal adenocarcinoma and a grade G3 well-differentiated neuroendocrine tumor (NET), on a background of chronic atrophic gastritis (Fig. 1). Unfortunately, examination of the NET component revealed intercepted margins. The patient is currently undergoing tumor staging and will be discussed by a multidisciplinary team to determine subsequent management.

Gastric adenocarcinomas are believed to be inflammation-driven tumors, mainly caused by *Helicobacter pylori* infection, associated with gastric atrophy and intestinal metaplasia. Gastric NETs are mostly related with elevated serum gastrin and enterochromaffin-like cell hyperplasia (2). Since atrophic gastritis can lead to hypergastrinemia, it might also

contribute to NET formation. Gastric MiNENs are mainly observed in elderly male patients and do not exhibit any specific endoscopic characteristic that allow them to be distinguished from adenocarcinoma (1). In this case, the diagnosis was made only after endoscopic resection.

Gastrointestinal MiNENs are exceptionally rare tumors, most frequently encountered in the colorectum (1). Other reported sites include the stomach, esophagus, small bowel, gallbladder, biliary tract and pancreas (1,3,4). The best approach to treatment is still debated (2,5), since they generally have a worse prognosis and a lower probability of successful endoscopic resection.

Conflicts of interest: the authors declare no conflict of interest.


José Damasceno e Costa<sup>1</sup>, Rita Seara Costa<sup>1</sup>,  
Hélder Devesa Moreira<sup>2,3</sup>, Aníbal Ferreira<sup>1</sup>

<sup>1</sup>Braga Hospital EPE, Braga, Portugal. <sup>2</sup>University Hospital Centre of Algarve, Faro, Portugal. <sup>3</sup>UNILABS – Laboratory of Pathological Anatomy, Porto, Portugal

DOI: 10.17235/reed.2023.9988/2023

### References

1. Elpek GO. Mixed neuroendocrine–nonneuroendocrine neoplasms of the gastrointestinal system: An update. *World J Gastroenterol* 2022;28(8):794-810. DOI: 10.3748/wjg.v28.i8.794
2. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. *Histopathology* 2020;76(2):182-8. DOI: 10.1111/his.13975
3. Arencibia Pérez B, Delgado Sánchez JJ, Marchena Gómez J. Mixed adenoneuroendocrine carcinoma of the colon - A complex and unique clinical duality. *Rev Esp Enferm Dig* 2021;113(11):796-7. DOI: 10.17235/reed.2021.7873/2021
4. Wang Q, Li L, Li J, et al. Mixed adenoneuroendocrine carcinoma of the gallbladder. *Rev Esp Enferm Dig* 2023 Apr 19;116. Epub ahead of print. DOI: 10.17235/reed.2023.9624/2023
5. Van Der Veen A, Seising MFJ, Wijnhoven BPL, et al. Management of resectable esophageal and gastric (mixed adeno)neuroendocrine carcinoma: A nationwide cohort study. *Eur J Surg Oncol* 2018;44(12):1955-62. DOI: 10.1016/j.ejso.2018.07.058



**Fig. 1.** Histological examination of the lesion showing the cyto-architectural features of the poorly differentiated intramucosal adenocarcinoma and the grade G3 well-differentiated neuroendocrine tumor (A), and immunohistochemical staining for chromogranin A, highlighting the neuroendocrine component (B).